Sen. Markwayne Mullin Purchases Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of Intuitive Surgical, Inc. (NASDAQ:ISRG). In a filing disclosed on January 16th, the Senator disclosed that they had bought between $15,001 and $50,000 in Intuitive Surgical stock on December 29th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Deere & Company (NYSE:DE) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Hilton Worldwide (NYSE:HLT) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of CocaCola (NYSE:KO) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 12/29/2025.
• Purchased $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/29/2025.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Boston Scientific (NYSE:BSX) on 12/29/2025.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $6.34 during mid-day trading on Friday, reaching $535.00. The stock had a trading volume of 3,013,414 shares, compared to its average volume of 1,454,295. The company has a market capitalization of $191.79 billion, a price-to-earnings ratio of 70.77, a price-to-earnings-growth ratio of 4.35 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The stock’s 50 day simple moving average is $566.32 and its two-hundred day simple moving average is $512.06.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.Intuitive Surgical’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 EPS. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently bought and sold shares of ISRG. Holos Integrated Wealth LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth approximately $25,000. Tobam grew its holdings in shares of Intuitive Surgical by 666.7% during the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 40 shares in the last quarter. Kilter Group LLC acquired a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $27,000. Olistico Wealth LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $28,000. Finally, Princeton Global Asset Management LLC purchased a new position in Intuitive Surgical during the second quarter valued at approximately $30,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Phase‑3 update on IS‑001 imaging drug — Intuitive advanced its Phase‑3 study aimed at reducing ureter injuries in robotic colorectal surgery, a safety-focused adjoint that could expand the company’s addressable offering and reinforce surgical‑safety differentiation. Intuitive Surgical Advances Phase 3 Imaging Drug
• Positive Sentiment: daVinci systems demand highlighted — Company commentary and industry coverage say system performance “exceeded expectations” and Intuitive is pushing for more placements, supporting procedure growth and recurring consumable revenue. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Positive Sentiment: Analyst support remains — At least some brokers (e.g., Bernstein) have reiterated buy ratings, signaling continued sell‑side conviction in ISRG’s long‑term growth profile despite near‑term noise. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Investor take: “buying the dip” narratives are emerging — Several bullish commentaries argue the pullback is an entry point given Intuitive’s wide moat, recurring consumables and procedure tailwinds. Intuitive Surgical: Buying The Dip On This Wide-Moat Compounder
• Neutral Sentiment: Analysts preparing for Q4 — Preview pieces outline the metrics (procedures, system placements, ASPs, margin drivers) that will matter when full Q4 results and guidance details arrive; these previews can amplify volatility around the print. Intuitive Surgical (ISRG) Q4 Earnings on the Horizon
• Neutral Sentiment: Brokerage commentary roundup — Coverage pieces remind investors that analyst ratings and model changes often move shares; they’re useful context but not a definitive signal by themselves. Brokers Suggest Investing in Intuitive Surgical (ISRG)
• Negative Sentiment: Preliminary Q4 revenue reaction — Although Intuitive reported strong preliminary Q4 and full‑year revenue growth, shares dipped as investors parsed procedure trends, margin dynamics and what management said about demand cadence. That disconnect between a beat and stock action is a key reason for the pullback. Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
• Negative Sentiment: Softer 2026 outlook flagged — Company commentary and reporting point to a softer 2026 outlook that trimmed forward expectations, which is the primary negative driver behind today’s weakness. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction analysis — Coverage asking “why did shares dive?” notes investors punished the stock for guidance/trajectory concerns despite the beat, illustrating that forward commentary and margin clarity matter more than one‑time beats. Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive?

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $547.36, for a total transaction of $2,463,120.00. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at $496,455.52. The trade was a 83.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Henry L. Charlton sold 13,731 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the completion of the sale, the executive vice president owned 3,056 shares of the company’s stock, valued at $1,772,480. This trade represents a 81.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 114,007 shares of company stock worth $63,533,844 over the last 90 days. 0.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ISRG. Hsbc Global Res upgraded shares of Intuitive Surgical to a “strong-buy” rating in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Monday, December 29th. Zacks Research raised shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a report on Friday, October 24th. Barclays reissued an “overweight” rating and issued a $686.00 price target (up previously from $635.00) on shares of Intuitive Surgical in a report on Wednesday, January 7th. Finally, Mizuho set a $575.00 target price on Intuitive Surgical in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $622.17.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.